Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL1B | P01584 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26258465 | 0.89 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL26258468 | 0.86 | CRBN (0.72) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL26258489 | 0.85 | CRBN (0.67) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL26258480 | 0.85 | CRBN (0.64) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL26258500 | 0.84 | CRBN (0.70) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL25269377 | 0.84 | CRBN (0.73) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL29377782 | 0.84 | CRBN (0.73) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL1962714 | 0.84 | CRBN (0.75) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL29381901 | 0.83 | DDB1 (0.59) | CRBNDDB1HDAC1HDAC2TNF | |
| SCHEMBL25222971 | 0.82 | CRBN (0.70) | CRBNDDB1HDAC1HDAC2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | CRBN 21/4885DDB1 550/4885HDAC1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.